NCT03104439View on ClinicalTrials.gov

Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

May 10, 2017

Primary Completion Date

January 31, 2026

Study Completion Date

April 30, 2027

Conditions
Microsatellite Stable Colorectal CancerPancreatic CancerMSI High Colorectal Cancer
Interventions
DRUG

Nivolumab

The antibodies in nivolumab work by causing programmed cell death of the cancer cells

DRUG

Ipilimumab

The antibodies in ipilimumab work by not allowing cancer cell growth

RADIATION

Radiation Therapy

Radiation therapy is believed to increase the likelihood of response of immunotherapy

Trial Locations (1)

02214

Massachusetts general Hospital, Boston

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT03104439 - Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer | Biotech Hunter | Biotech Hunter